DYNAVAX TECHNOLOGIES news, videos and press releases - Page 4
For more news please use our advanced search feature.
DYNAVAX TECHNOLOGIES - More news...
DYNAVAX TECHNOLOGIES - More news...
- Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
- Dynavax to Present at the William Blair 41st Annual Growth Stock Conference
- Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering
- Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
- Dynavax Announces First Quarter 2021 Financial Results
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR)
- Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
- Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results
- Dynavax to Present at the Cowen 41st Annual Health Care Conference
- Dynavax to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 25, 2021
- Dong Yu, Ph.D., Joins Dynavax as Senior Vice President of Vaccine Research
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018
-
Dynavax Technologies Corporation - DVAX Stock Chart Technical Analysis for 02-01-2021
- Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government
- Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response
- Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
- Dynavax Appoints Kelly MacDonald as Chief Financial Officer
- Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
- Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
- European CHMP Adopts Positive Opinion for HEPLISAV-B®, Dynavax's Two Dose Adult Hepatitis B Adjuvanted Vaccine
- Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference
- Thinking about buying stock in Virgin Galactic, Glu Mobile, Coty, Cloudflare, or Dynavax Technologies?
- Dynavax Announces Third Quarter 2020 Financial Results
